Q3 2022 Valneva SE Earnings Call Transcript
Good day, and thank you for standing by. Welcome to the Valneva reports 9 Month 2022 results and provides corporate updates call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Thomas Lingelbach, CEO. Please go ahead.
Thank you. Very good day, everyone. Pleasure to welcome you to our 9 months results and update call. Yes, the 9 months have again been marked with quite a substantial number of key achievements.
We stand today at the 9-month revenue level of about EUR 250 million at a level of 3.5x compared to 2021. We have a very strong cash position with more than EUR 260 million at the end of September, which excludes the proceeds from the recent global offering. Our chikungunya vaccine candidate progresses very nicely towards licensure. The rolling submission for BLA with U.S. FDA is ongoing and expect it to complete by the end of 2022.
On our Lyme
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |